Researchers who tested the vaccine in a combined Phase 1-2 trial — mostly meant to show safety — found either one or two doses of the vaccine generated both antibody and T-cell responses against the coronavirus. The trials were not designed to show whether the vaccine protected people against either infection or symptoms of coronavirus — that’s what the ongoing Phase 3 trials are designed to do.
COVID-19